Historical review from 2026-11-15. Current price and availability are unconfirmed; check the original marketplace.
Stacker is a verified iPhone app in the growing peptide/biohacking niche generating $447/mo in profit on $456/mo revenue — an extraordinary 98% margin that reflects minimal operating costs. The $15,000 asking price works out to a 2.8x annual profit multiple, which is reasonable for a niche mobile app. However, revenue at ~$456/mo is modest in absolute terms, and the business age is not disclosed, leaving the durability of the customer base an open question. Platform verification adds meaningful credibility to the financials.
The core software — a mobile dose tracker with reminders and progress logging — is reproducible by a capable solo founder using AI-assisted development tools, SwiftUI or React Native, and a managed backend for roughly $2K–$6K in out-of-pocket costs over 6 weeks. However, the buy case rests on the verified recurring revenue stream and any existing App Store reviews, search ranking, and user base that would take additional time to rebuild. The verdict leans buy given the low multiple and verified profit, but the missing user-count and retention data temper confidence — a buyer should request those figures before closing.
Cash estimate includes the AI tools, APIs and infrastructure needed for a solo founder to recreate the software. Build time is informational and lightly weighted. The verdict is driven mainly by customers, users, verified earnings, retention, distribution, brand, data and operating history.
Helps users build personalized peptide stacks, log doses, get reminders, and track protocol progress and results in one iPhone app.
Opens the original listing on TrustMRR
Get new listings with asking prices, monthly profit, deal scores, and key risks.
The best reviewed deals, concise and evidence-first. Unsubscribe anytime.
Preliminary screening based on marketplace and public data. Verify all financial, legal, technical, customer, and operational claims independently before making an acquisition decision. This is not financial or legal advice.